Professor Scott Williams is a radiation oncologist who works exclusively with urological cancers, and in particular, prostate cancer. He is Professor of Oncology at University of Melbourne and Honorary Professor of Medicine at University of Queensland. Scott has an international profile as the lead of several large global studies of hormonal therapy combined with radiotherapy in prostate cancer, while also managing multiple smaller studies locally and nationally. His research largely focuses on how prostate cancer responds to radiation therapy (in particular related to brachytherapy), including recent molecular and immune system insights derived from extensive laboratory investigations. Other avenues of work involve global collaborations to evaluate outcomes measures used in clinical trials, along with a large body of work evaluating novel imaging and targeted radio-isotope therapy in prostate cancer.
As the chair of the prostate cancer subcommittee of Australia’s national multidisciplinary clinical trials group for urological cancers (ANZUP) for over a decade, he plays a key role in developing and managing numerous clinical trials at the national and international level. He is part of numerous national and international advisory, academic and research funding bodies related to prostate and other cancers, such as the Cancer Council Victoria and Prostate Cancer Foundations of Australia and USA. He has published extensively, including being the lead author on global prostate cancer management papers for The Lancet and The Lancet Oncology, as well as key publications in the New England Journal of Medicine and the Journal of Clinical Oncology, amongst others.
Prostate Cancer Foundation (USA) Creativity Award (2010): this international award recognises innovative research into prostate cancer. The only occasion that this award has gone outside of North America.